harvard
bioscience
announces
third
quarter
financial
results
operating
margin
gaap
adjusted
basis
revenue
improved
sequentially
solid
cro
pharma
demand
academic
labs
reopening
generated
positive
operating
cash
flow
working
capital
improvements
holliston
globe
newswire
harvard
bioscience
nasdaq
hbio
company
today
announced
financial
results
three
nine
months
ended
september
jim
green
chairman
ceo
said
since
anticipating
academic
labs
around
world
would
likely
experience
shutdowns
early
year
moved
aggressively
manage
costs
actions
combined
restructuring
programs
reduced
overall
cost
operations
delivering
adjusted
operating
income
margin
green
concluded
continued
growth
cro
pharma
customers
reopening
academic
labs
lower
cost
operations
expected
drive
solid
operating
margins
throughout
rest
allow
targeted
commercial
product
investments
drive
revenue
growth
expect
adjusted
operating
margins
second
half
mid
upper
quarterly
financial
results
summary
revenue
million
million
million
operating
income
loss
gaap
million
million
million
adjusted
operating
income
million
million
million
adjusted
operating
margin
loss
per
diluted
share
gaap
diluted
eps
gaap
adjusted
diluted
eps
million
million
million
debt
outstanding
less
cash
cash
equivalents
please
refer
exhibits
reconciliation
certain
gaap
financial
measures
including
operating
income
net
income
loss
diluted
earnings
per
share
please
see
use
financial
information
additional
information
regarding
use
adjusted
financial
information
webcast
conference
call
details
harvard
bioscience
hosting
conference
call
webcast
today
eastern
time
access
live
conference
call
dialing
following
phone
numbers
international
referencing
conference
id
conference
call
simultaneously
webcast
accessed
harvard
bioscience
website
slide
presentation
referenced
webcast
posted
investor
relations
website
shortly
webcast
begins
listen
webcast
log
webcast
http
click
earnings
call
icon
use
financial
information
press
release
included
financial
information
including
adjusted
operating
income
adjusted
net
income
adjusted
diluted
earnings
per
share
believe
financial
information
provides
investors
enhanced
understanding
underlying
operations
business
periods
presented
financial
measures
excluded
certain
expenses
income
primarily
resulting
purchase
accounting
events
believe
related
underlying
operations
business
amortization
intangibles
related
acquisitions
costs
related
acquisition
disposition
integration
initiatives
impairment
charges
severance
restructuring
business
transformation
expenses
compensation
expense
also
exclude
tax
impact
reconciling
items
financial
information
approximates
information
used
management
internally
evaluate
operating
results
company
tabular
reconciliations
adjusted
operating
income
adjusted
net
income
loss
adjusted
earnings
loss
per
diluted
share
included
exhibits
press
release
financial
information
provided
press
release
considered
addition
substitute
financial
information
provided
presented
accordance
gaap
may
different
companies
financial
information
harvard
bioscience
harvard
bioscience
leading
developer
manufacturer
seller
technologies
products
services
enable
fundamental
research
discovery
testing
drug
development
customers
range
renowned
academic
institutions
government
laboratories
world
leading
pharmaceutical
biotechnology
clinical
research
organizations
operations
north
america
europe
china
sell
combination
direct
distribution
channels
customers
around
world
information
please
visit
website
statements
press
release
contains
statements
within
meaning
federal
securities
laws
including
private
securities
litigation
reform
act
identify
statements
use
words
guidance
objectives
optimistic
potential
future
expects
plans
estimates
continue
drive
strategy
potential
potentially
growth
projects
projected
intends
believes
goals
sees
seek
develop
possible
new
emerging
opportunity
pursue
similar
expressions
relate
historical
matters
statements
press
release
may
made
conference
call
may
include
limited
statements
inferences
company
management
beliefs
expectations
company
anticipated
future
revenues
earnings
strength
company
market
position
business
model
industry
outlook
impact
pandemic
company
business
company
business
strategy
positioning
company
growth
market
demand
opportunity
company
current
products
products
developing
intends
develop
company
plans
objectives
intentions
historical
facts
statements
involve
known
unknown
risks
uncertainties
factors
may
cause
company
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
investors
note
many
factors
fully
described
caption
risk
factors
annual
report
form
year
ended
december
quarterly
reports
form
issued
filings
securities
exchange
commission
otherwise
enumerated
herein
therein
may
cause
company
actual
results
differ
materially
statements
statements
press
release
qualified
risk
factors
company
results
may
also
affected
factors
company
currently
aware
company
may
update
statements
even
though
situation
may
change
future
unless
obligations
federal
securities
laws
update
disclose
material
developments
related
previously
disclosed
information
investor
inquiries
please
contact
michael
rossi
chief
financial
officer
harvard
bioscience
consolidated
statements
operations
unaudited
thousands
except
per
share
data
three
months
ended
september
june
september
revenues
cost
revenues
gross
profit
operating
expenses
sales
marketing
expenses
general
administrative
expenses
research
development
expenses
amortization
intangible
assets
impairment
charges
total
operating
expenses
operating
income
loss
expense
interest
expense
net
expense
income
net
expense
loss
income
taxes
income
tax
provision
benefit
net
loss
basic
diluted
loss
per
share
weighted
average
common
shares
basic
diluted
harvard
bioscience
consolidated
statements
operations
unaudited
thousands
except
per
share
data
nine
months
ended
september
september
revenues
cost
revenues
gross
profit
operating
expenses
sales
marketing
expenses
general
administrative
expenses
research
development
expenses
amortization
intangible
assets
impairment
charges
total
operating
expenses
operating
loss
expense
interest
expense
net
expense
net
expense
loss
income
taxes
income
tax
provision
benefit
net
loss
basic
diluted
loss
per
share
weighted
average
common
shares
basic
diluted
harvard
bioscience
condensed
consolidated
balance
sheets
unaudited
thousands
september
december
assets
cash
cash
equivalents
accounts
receivables
inventories
current
assets
total
current
assets
property
plant
equipment
goodwill
intangibles
assets
total
assets
liabilities
stockholders
equity
current
portion
debt
current
liabilities
total
current
liabilities
debt
liabilities
stockholders
equity
total
liabilities
stockholders
equity
harvard
bioscience
condensed
consolidated
statements
cash
flows
unaudited
thousands
nine
months
ended
september
september
cash
flows
operating
activities
net
loss
changes
operating
assets
liabilities
adjustments
operating
cash
flows
net
cash
provided
operating
activities
cash
flows
investing
activities
additions
property
plant
equipment
disposition
business
investing
activities
net
cash
used
provided
investing
activities
cash
flows
financing
activities
proceeds
borrowings
repayments
debt
financing
activities
net
cash
used
financing
activities
effect
exchange
rate
changes
cash
decrease
cash
cash
equivalents
cash
cash
equivalents
beginning
period
cash
cash
equivalents
end
period
harvard
bioscience
reconciliation
gaap
financial
measures
unaudited
thousands
except
per
share
data
three
months
ended
september
june
september
gaap
operating
income
loss
compensation
expense
severance
restructuring
transformation
costs
acquired
intangible
assets
amortization
impairments
expense
acquisition
accounting
adjusted
operating
income
gaap
operating
margin
adjusted
operating
margin
gaap
net
loss
compensation
expense
severance
restructuring
transformation
costs
acquired
intangible
assets
amortization
impairments
expense
acquisition
accounting
income
taxes
adjusted
net
income
gaap
loss
per
diluted
share
adjusted
items
tax
per
share
assuming
dilution
adjusted
earnings
per
diluted
share
weighted
average
diluted
common
shares
gaap
adjusted
income
taxes
includes
tax
effect
adjustments
gaap
results
harvard
bioscience
reconciliation
gaap
financial
measures
unaudited
thousands
except
per
share
data
nine
months
ended
september
september
gaap
operating
loss
income
compensation
expense
severance
restructuring
transformation
costs
acquired
intangible
assets
amortization
impairments
expense
acquisition
accounting
adjusted
operating
income
gaap
operating
margin
adjusted
operating
margin
gaap
net
loss
compensation
expense
severance
restructuring
transformation
costs
acquired
intangible
assets
amortization
impairments
expense
acquisition
accounting
income
taxes
adjusted
net
income
gaap
loss
per
diluted
share
adjusted
items
tax
per
share
assuming
dilution
adjusted
earnings
per
diluted
share
weighted
average
diluted
common
shares
gaap
adjusted
income
taxes
includes
tax
effect
adjustments
gaap
results
